Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

Design Therapeutics, Inc.

Contributing Author

Recent Articles by Design Therapeutics, Inc.

Sep-02	Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference DSGN GlobeNewswire
Aug-03	Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results DSGN GlobeNewswire
Jun-30	Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 DSGN GlobeNewswire
May-28	Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference DSGN GlobeNewswire
May-18	Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia DSGN -25.54% GlobeNewswire
May-17	Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026 DSGN GlobeNewswire
Apr-28	Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates DSGN DSGN +23.26% GlobeNewswire
Mar-09	Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates DSGN GlobeNewswire
Feb-18	Design Therapeutics to Participate in Upcoming Investor Conferences DSGN GlobeNewswire
Nov-26	Design Therapeutics to Participate in Upcoming Investor Conferences DSGN GlobeNewswire
Nov-05	Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results DSGN GlobeNewswire
Sep-10	Design Therapeutics Appoints Justin Gover to Board of Directors DSGN -7.68% GlobeNewswire
Aug-27	Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference DSGN GlobeNewswire
Aug-07	Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results DSGN -8.74% DSGN +7.81% GlobeNewswire
Jun-04	Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 DSGN GlobeNewswire
May-28	Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference DSGN GlobeNewswire
May-13	Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference DSGN GlobeNewswire
May-07	Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results DSGN -8.26% DSGN +5.71% GlobeNewswire
May-01	Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy DSGN GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)